1. American Cancer Society (2005) Cancer Facts and Figures. Atlanta, Ga
2. American Society of Clinical Oncology. Use of hematopoietic colony-stimulating factors: evidence-based, practice guidelines
3. Del Campo J, Roszak A, Ciuleanu T, Bidzinski M, Hogberg T, Wojtukienicz M, Boman K, Poveda A, Westermann A, Izquierdo M (2006) Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. ASCO Ann Meet Proc 24: 5031
4. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97–105
5. Garcia AA, O'Meara A, Bahador A, Facio G, Jeffers S, Kim DY, Roman L (2004) Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 93: 493–498